Malignant lymphoma
Conditions
Interventions
Palonostron 0.75mg/body is administrated before chemotherapy. Palonpstron is administrated on day1 in the first course of chemotherapy.
Sponsors
Shimane University Hospital,cancer center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Age of patient is more than 20 years old. 2)Patient is diagnosed as malignant lymphoma. 3)Patient is planned to received high-risk chemotherapy induced nausea and vomiting as below:CHOP,ESHAP,EPOCH,ABVd/Hyper-CVAD/MA,ICE,DeVIC,C-MOPP,CPA. 4)Patient has sufficient organ functio. 5)Patient has no ECG abnormality require treatment. 6)Performance Status(ECOG scale)of patient is 0 to 2. 7)Patient consent to participate in the study by writing.
Exclusion criteria
Exclusion criteria: 1)Patient has severe complication require treatment. 2)Patient has more than CTCAE grade1 nausea and vomiting before chemotherapy. 3)Patient has hypersensitivity of Palonosetron or the other 5-HT3 antagonist. 4)Pregnant or nursing women. Patient refuses to contraception. 5)Patient is deemed inappropriate by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response during chemotherapy | — |
Countries
Japan
Contacts
Public ContactTsutomu Takahahsi
Shimane University Hospital Cancer center
Outcome results
None listed